Deferasirox是具有口服活性的铁离子过量螯合剂，同时可诱导细胞色素P450 3A4，抑制细胞色素P450 2C8及1A2；其通过螯合铁离子导致的铁损耗，可促进BclxL下调并诱导细胞死亡。
| 英文别名 (English Synonym) | Deferasirox |
| 中文名称 (Chinese Name) | 地拉罗司 |
| 靶点 (Target) | Cyclin-Dependent Kinases |
| 通路 (Pathway) | Cell Cycle/DNA Damage |
| CAS号 (CAS NO.) | 201530-41-8 |
| 分子式 (Formula) | C21H15N3O4 |
| 分子量 (Molecular Weight) | 373.37 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Sobbe A, Bridle KR, Jaskowski L, de Guzman CE, Santrampurwala N, Clouston AD, Campbell CM, Subramaniam VN, Crawford DH. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30(3):638-45. doi: 10.1111/jgh.12720. PMID: 25168203.[2]Kim JL, Kang HN, Kang MH, Yoo YA, Kim JS, Choi CW. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase. Acta Haematol. 2011;126(4):241-5. doi: 10.1159/000330608. Epub 2011 Sep 27. PMID: 21951998.[3]Lee DH, Jang PS, Chung NG, Cho B, Jeong DC, Kim HK. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41(6):539-46. doi: 10.1016/j.exphem.2013.02.004. Epub 2013 Feb 13. PMID: 23415674.
